What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
. Am J Ther. 2021 Sep-Oct 01;28(5):e579-e580. doi: 10.1097/MJT.0000000000001443. Am J Ther. 2021. PMID: 34491955 Free PMC article.
.
Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
.
. Physiol Rev. 2021 Sep 6. doi: 10.1152/physrev.00028.2020. Online ahead of print. Physiol Rev. 2021. PMID: 34486393